Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know

Core Viewpoint - Adma Biologics (ADMA) shares have increased by 22.2% in the past four weeks, closing at $19.65, with a potential upside of 39.1$27.33 [1] Price Targets - The average price target consists of three estimates ranging from a low of $25 to a high of$32, with a standard deviation of $4.04, indicating a potential increase of 27.2% to 62.9% from the current price [2] - A low standard deviation suggests a strong agreement among analysts regarding the price movement of ADMA shares, which can serve as a starting point for further research [7] Analyst Sentiment - Analysts have shown increasing optimism about ADMA's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - Over the last 30 days, two earnings estimates for ADMA have been revised upward, leading to a 3.7% increase in the Zacks Consensus Estimate [10] Zacks Rank - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [11] Conclusion on Price Targets - While consensus price targets may not be entirely reliable for predicting stock gains, they can provide a useful guide for understanding potential price movements [12]